Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases.

Published in: ACS medicinal chemistry letters (2024)

The invention in this patent application relates to macrocyclic benzimidazole derivatives represented herein generally by Formula 1. The compounds of Formula 1 are cGAS inhibitors and may potentially provide treatments of autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, and others.

Keyphrases

systemic sclerosis
systemic lupus erythematosus
interstitial lung disease
human milk
multiple sclerosis
disease activity
protein kinase
molecular docking
rheumatoid arthritis
risk assessment
pseudomonas aeruginosa
cystic fibrosis
climate change
drug induced
human health
structure activity relationship